EM-T3Expert Opinion on Drug Safety2024-10-18第 24 卷第 12 期，1443-1451
Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting System
